Hospital
Good Samaritan Hospital
Good Samaritan Hospital was paid $15.85M by Medicaid between Jan 2018 and Dec 2024, across 151 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoGOOD SAMARITAN HOSPITAL
VINCENNES, IN 47591
VINCENNES, IN 47591
33aNPI1225032881assigned 06/10/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.85M
24GClaims444,853
24DCodes billed151
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#26 of 69
Median peer was paid$9.76M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 61,211 | $868K | |
| 2019 | 53,361 | $1.57M | |
| 2020 | 46,436 | $1.56M | |
| 2021 | 66,991 | $2.58M | |
| 2022 | 88,128 | $3.55M | |
| 2023 | 75,167 | $3.36M | |
| 2024incomplete | 53,559 | $2.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 34,634 | 29,798 | $4.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 30,445 | 24,165 | $3.14M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 16,346 | 13,257 | $1.68M |
| 71045 | Radiologic examination, chest; single view | 5.3% | 7,786 | 6,176 | $833K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.8% | 11,318 | 8,964 | $598K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.0% | 4,562 | 3,905 | $477K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.0% | 14,722 | 11,263 | $471K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.7% | 4,429 | 3,725 | $433K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 5,254 | 4,584 | $332K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.8% | 1,064 | 816 | $279K |
| 80050 | General health panel | 1.7% | 1,740 | 1,498 | $265K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 5,022 | 3,787 | $238K |
139 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 1,378 | $235K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.4% | 2,569 | $225K |
| 80053 | Comprehensive metabolic panel | 1.3% | 47,497 | $208K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 7,994 | $195K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 59,591 | $193K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,303 | $156K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,776 | $150K |
| 20610 | <1% | 812 | $133K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 76,083 | $129K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,790 | $116K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,129 | $103K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 564 | $86K |
| 99218 | <1% | 200 | $73K | |
| 80061 | Lipid panel | <1% | 10,065 | $70K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 536 | $70K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 354 | $60K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 496 | $57K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 382 | $43K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,173 | $39K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,194 | $35K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 160 | $35K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 936 | $35K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,486 | $31K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,117 | $31K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,114 | $31K |
| 84484 | <1% | 5,110 | $29K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 71 | $29K |
| 81001 | <1% | 17,943 | $26K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,191 | $22K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,688 | $18K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 150 | $18K |
| 64493 | <1% | 15 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,524 | $14K |
| 87522 | Neg quan hep c or qual rna | <1% | 396 | $12K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 475 | $10K |
| G0378 | Hospital observation service, per hour | <1% | 160 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 476 | $10K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 16 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 484 | $9K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 437 | $8K |
| 82550 | <1% | 2,768 | $8K | |
| 36591 | <1% | 382 | $8K | |
| 88142 | <1% | 667 | $7K | |
| 80348 | <1% | 198 | $6K | |
| 84703 | <1% | 1,411 | $6K | |
| 80365 | <1% | 213 | $6K | |
| 87070 | <1% | 719 | $6K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 42 | $5K |
| 59020 | <1% | 16 | $5K | |
| 83605 | <1% | 963 | $4K | |
| 83690 | <1% | 1,535 | $4K | |
| 80320 | <1% | 273 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 80 | $4K |
| 86803 | <1% | 381 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 49 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,222 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 49 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $3K |
| 87040 | <1% | 460 | $3K | |
| 64494 | <1% | 14 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 140 | $3K |
| 84439 | <1% | 384 | $2K | |
| 80074 | <1% | 56 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 51 | $2K |
| 82248 | <1% | 623 | $2K | |
| 86762 | <1% | 193 | $2K | |
| 85610 | <1% | 1,262 | $1K | |
| 87340 | <1% | 271 | $1K | |
| 86592 | <1% | 481 | $1K | |
| 80361 | <1% | 213 | $1K | |
| 85730 | <1% | 593 | $1K | |
| 82607 | <1% | 154 | $1K | |
| 95806 | <1% | 12 | $1K | |
| 84702 | <1% | 102 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 122 | $1K |
| 82043 | <1% | 353 | $1K | |
| 86885 | <1% | 299 | $981.27 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 51 | $886.71 |
| 83735 | <1% | 415 | $737.40 | |
| 94060 | <1% | 15 | $596.31 | |
| 83880 | <1% | 33 | $567.47 | |
| 86677 | <1% | 169 | $547.09 | |
| 84145 | <1% | 28 | $484.22 | |
| 86696 | <1% | 29 | $483.75 | |
| 86665 | <1% | 17 | $435.36 | |
| 86901 | <1% | 239 | $428.98 | |
| 86900 | <1% | 239 | $426.08 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 14 | $421.08 |
| 87653 | <1% | 13 | $404.67 | |
| 87077 | <1% | 178 | $344.94 | |
| 86695 | <1% | 29 | $329.75 | |
| 83655 | <1% | 29 | $302.72 | |
| 82728 | <1% | 31 | $293.67 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 56 | $221.62 |
| 84207 | <1% | 21 | $218.08 | |
| 86140 | <1% | 87 | $215.48 | |
| 94761 | <1% | 14 | $196.40 | |
| 82542 | <1% | 21 | $184.00 | |
| 86664 | <1% | 17 | $183.48 | |
| 84100 | <1% | 110 | $166.30 | |
| 83540 | <1% | 28 | $156.31 | |
| 85379 | <1% | 30 | $152.70 | |
| 83921 | <1% | 13 | $148.23 | |
| 82746 | <1% | 29 | $128.34 | |
| 86704 | <1% | 15 | $119.06 | |
| 86706 | <1% | 15 | $106.12 | |
| 86705 | <1% | 15 | $104.88 | |
| 82950 | <1% | 27 | $79.52 | |
| 87186 | <1% | 133 | $70.92 | |
| 87205 | <1% | 18 | $70.77 | |
| 83550 | <1% | 12 | $69.92 | |
| 86308 | <1% | 17 | $62.16 | |
| 82570 | <1% | 29 | $50.42 | |
| 84630 | <1% | 22 | $50.08 | |
| 85652 | <1% | 31 | $34.54 | |
| 87088 | <1% | 90 | $22.03 | |
| 88738 | <1% | 15 | $21.10 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,346 | $2.96 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,455 | $0.95 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,628 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,532 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 1,166 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 3,027 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 12 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 494 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 1,161 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 58 | $0.00 |
| 96376 | 0% | 15 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 297 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 51 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 57 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 20 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 873 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 225 | $0.00 |
| 94729 | 0% | 15 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 16 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 20 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHACKER, ADAM (CEO)
| Provider | Location | Paid |
|---|---|---|
| Good Samaritan Hospital Physician Services, INC | Vincennes, IN | $9.81M |
| Good Samaritan Hospital | Vincennes, IN | $8.79M |
| Good Samaritan Hospital Physicians Services INC | Vincennes, IN | $3.55M |
| Good Samaritan Hospital | Vincennes, IN | $144K |
| Good Samaritan Hospital | Vincennes, IN | $62K |
| Good Samaritan Hospital | Vincennes, IN | $36K |
| Good Samaritan Hospital | Vincennes, IN | $22K |
| Good Samaritan Hospital | Vincennes, IN | $8K |
| Good Samaritan Hospital | Vincennes, IN | $949.56 |
| Good Samaritan Hospital | Vincennes, IN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.